Helus Pharma Appoints Former Pfizer CMO Dr. Freda Lewis-Hall to Board and Scientific Advisory Chair
HELP sits 53% above its 52-week low of $4.81.
Summary
Helus Pharma, operating as Cybin Inc., has appointed Dr. Freda Lewis-Hall, former Pfizer Chief Medical Officer, to its Board of Directors and as Chair of its Scientific Advisory Committee, significantly bolstering its clinical and regulatory expertise.
Key Events · Executive and Board Changes · HELP
-
High-Profile Board Appointment
Dr. Freda Lewis-Hall, a distinguished physician and biopharmaceutical executive, has been appointed to Helus Pharma's Board of Directors.
-
Scientific Advisory Committee Leadership
Dr. Lewis-Hall will also serve as Chair of the Company's Scientific Advisory Committee, guiding clinical development and regulatory strategy.
-
Extensive Industry Experience
Her background includes over a decade as Executive Vice President and Chief Medical Officer at Pfizer, as well as senior leadership roles at Vertex Pharmaceuticals, Bristol Myers Squibb, and Eli Lilly and Company.
-
Strategic Enhancement for Clinical-Stage Company
This appointment is crucial for a clinical-stage pharmaceutical company like Helus Pharma, providing invaluable expertise in advancing its novel serotonergic agonist (NSA) portfolio for mental health conditions.
Analysis · HELP · Life Sciences
The appointment of Dr. Freda Lewis-Hall, a former Chief Medical Officer at Pfizer and a seasoned biopharmaceutical executive, to both the Board of Directors and as Chair of the Scientific Advisory Committee is a highly significant development for Helus Pharma (Cybin Inc.). Her extensive experience in clinical development, regulatory engagement, and global commercialization, particularly in mental health, provides a substantial boost to the company's credibility and strategic capabilities. This move follows recent positive Phase 2a clinical trial results and a substantial $175 million financing round, indicating a strategic focus on strengthening leadership to advance its novel serotonergic agonist (NSA) pipeline and execute on its growth plans.
At the time of this filing, HELP was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $4.81 to $9.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.